Over the course of a quarter of a century, Mr. Rein has handled numerous patent litigations relating to a wide variety of pharmaceuticals including generic versions of well-known products such as CLARITIN, LIPITOR and ZANTAC. In recent litigation relating to Teva’s generic version of NASONEX, Mr. Rein secured a trial victory based on his examination of the parties’ expert witnesses including Merck’s expert who used one of the world’s most powerful X-ray diffraction facilities, the synchrotron at Argonne National Laboratory, in an unsuccessful attempt to prove infringement.
Prior to joining Goodwin in 2001 to help start its IP law practice in New York, Mr. Rein was a partner at a well-known IP law firm. Earlier in his career, he clerked at the U.S. District Court for the Central District of California (located in Los Angeles). He previously served on the Patents Committee of the Association of the Bar of the City of New York and is currently involved in the Israel Practice committee of the American Intellectual Property Law Association and the Tech Division committee of UJA.